B+
Bull case
25%
Probability
Target price
$41.00
Analysis reference price unavailable
Analysis 2026-10-11 · RankAlpha Sentiment Codex
KEQU
Kewaunee ScientificANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Sequential backlog growth, stronger education-market activity and a higher-margin international project mix could support recovery if project releases translate into manufacturing volume. [#SEC-8K-2026-09-09]
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
A higher international earnings mix raised the effective tax rate, while additional corporate compensation expense pressured Q1 profitability; the company said the incremental expense was not expected to recur. [#SEC-8K-2026-09-09]
Momentum
75
Value
72
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $34.00 · Bull $41.00 · Bear $26.00Analysis 2026-10-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Why
Momentum75 · Δ7d -
Value72 · Δ7d -0.1
Sentiment50 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • A higher international earnings mix raised the effective tax rate, while additional corporate compensation expense pressured Q1 profitability; the company said the incremental expense was not expected to recur. [#SEC-8K-2026-09-09]
- • Backlog of $169.0 million remained below the $205.0 million year-earlier level, leaving conversion and project timing uncertain. [#SEC-8K-2026-09-09]
- • Backlog remains below its year-earlier level, and Q1 sales, EPS and EBITDA declined.
Catalyst clock
2026-12-31
Lab Products Group volume pressure
Lead driver: Value · See fundamentals
Momentum
75
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
72
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.1
Sentiment
50
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 74.8 / Value 71.6 / Sentiment 49.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-11. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-10-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-10-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$96.21M
Beta
0.56
Shares Out
2.9M
P/E (TTM)
9.8
P/S (TTM)
0.39
P/FCF (TTM)
5.88
Rev YoY
-7.5%
EPS YoY
-30.5%
Gross Margin
+28.5%
Op Margin
+5.9%
Net Debt
$45.2M
Current Ratio
2.18
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data